Novo Nordisk’s NOVO.B-0.23%decrease; red down pointing triangle Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish ...

The question of who targeted the residents of besieged Sarajevo through sniper scopes during the Bosnian War has gone unanswered for three decades. Whether some of these individuals paid to kill women ...

Novo Nordisk A/S (NVO), though cheap at 13x forward earnings, is in my view a value trap, as growth is slowing and GLP-1 pricing pressures are capping revenue and profitability. The TrumpRx platform ...

Denmark's seasonally adjusted gross domestic product grew by 2.3% in the third quarter, a preliminary reading from Statistics Denmark showed early Thursday. The main driver of growth was the ...

Bosnian Serb forces laid siege to Sarajevo in Bosnian war Milan prosecutors launch probe three decades after siege Sarajevans welcome probe although it reopens old wounds SARAJEVO, Nov 18 (Reuters) - ...

Novo Nordisk is cutting the out-of-pocket prices of its popular weight-loss drug Wegovy and diabetes drug Ozempic for some consumers. Current customers who pay for the drugs out of pocket — without ...

Another quarterly earnings announcement from Novo Nordisk and another downgrade to earnings guidance from the Danish pharmaceuticals company, the fourth this year. Jules Rimmer is a markets reporter ...

Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs like Zepbound and Wegovy in exchange for tariff relief and ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Matthew Herper covers ...

Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to gain access to a promising liver disease drug candidate, in the first major deal by the Danish ...

Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the pharmaceutical concern has entered an agreement to purchase U.S.-based peer Akero Therapeutics Inc ...

Novo Nordisk A/S is working on a strategy to make obesity treatment more personalized and wants to offer options for every kind of patient. The Danish company envisions a trajectory of treatment that ...